In accordance with the publicity guidelines, press releases referring to the offering were added to Median Technologies’ website regular press release list on Sept. 21, 2023, i.e. more than 40 calendar days following the determination by the CEO acting upon delegation of the board of directors of the Company of the price for the shares to be issued by the Company in the Offering. Press releases referring to the Offering are now available without a special screening mechanism that restricts persons resident in restricted countries from accessing press releases.
Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We harness the power of medical images by using the most advanced Artificial Intelligence technologies, to increase the accuracy of diagnosis and treatment of many cancers and other metabolic diseases at their earliest stages and provide insights into novel therapies for patients. Our iCRO solutions for medical image analysis and management in oncology trials and eyonis™, our AI/ML tech-based suite of software as medical devices (SaMD), help biopharmaceutical companies and clinicians to bring new treatments and diagnose patients earlier and more accurately. This is how we are helping to create a healthier world.